Eri L M, Tveter K J
Department of Surgery, Ullevaal University Hospital, Oslo, Norway.
J Urol. 1994 Aug;152(2 Pt 1):448-52. doi: 10.1016/s0022-5347(17)32760-x.
The luteinizing hormone releasing hormone agonist leuprolide was investigated in a double-blind, randomized, placebo-controlled study comprising 50 evaluable patients with moderate to severe symptoms resulting from benign prostatic hyperplasia. Patients received 3.75 mg. leuprolide depot or placebo as an injection every 28 days for 24 weeks. Hemoglobin level decreased by 0.8 gm/100 ml. (p = 0.0052) for patients receiving leuprolide. Mean testicular volume decreased by 28.9% (p < 0.001) compared to placebo. Of 26 patients receiving leuprolide 5 had a weight gain of more than 3 kg. Almost all patients receiving leuprolide experienced hot flushes. Breast changes, and loss of energy and vigor were not more pronounced than for patients receiving placebo. Erectile function and sexual activity were lost during treatment. Libido also decreased but was still partially retained. Despite this, patients receiving leuprolide were generally contented with their sexual life during treatment. Side effects were bothersome for some patients but were reversible. Of the patients in our study 73% expressed that they could repeat or continue treatment if that had been possible. The high cost of these drugs will limit their use for a benign condition, such as benign prostatic hyperplasia.
在一项双盲、随机、安慰剂对照研究中，对促黄体生成素释放激素激动剂亮丙瑞林进行了研究，该研究纳入了50例可评估的良性前列腺增生导致中度至重度症状的患者。患者每28天接受一次3.75mg亮丙瑞林长效注射剂或安慰剂注射，共24周。接受亮丙瑞林治疗的患者血红蛋白水平下降了0.8g/100ml（p = 0.0052）。与安慰剂相比，平均睾丸体积下降了28.9%（p < 0.001）。在26例接受亮丙瑞林治疗的患者中，有5人体重增加超过3kg。几乎所有接受亮丙瑞林治疗的患者都经历了潮热。乳房变化、精力和活力丧失并不比接受安慰剂治疗的患者更明显。治疗期间勃起功能和性活动丧失。性欲也下降，但仍部分保留。尽管如此，接受亮丙瑞林治疗的患者在治疗期间总体上对性生活感到满意。副作用对一些患者来说很困扰，但可以逆转。在我们研究的患者中，73%表示如果有可能，他们会重复或继续治疗。这些药物的高成本将限制其在良性疾病如良性前列腺增生中的应用。
